Crescent Biopharma, Inc.

CBIONASDAQHealthcare● Active

$18.15

+$0.87(+5.01%)

Market Cap$500319697

P/E Ratio—

52W High$27.41

52W Low$8.72

Avg Volume276K

Open$17.38

Beta1.15

Insider Trades Ownership Employees

Crescent Biopharma, Inc. (CBIO) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · CBIO · as of Jun 9, 2026

Activity summary

Buy transactions

P-Purchase only

Sell transactions

12 Months

Buy/Sell ratio

∞

Buy/Sell (by trades)

Overall sentiment

BULLISH

↑ Buy 100%Active transactions only · RSU vesting excluded0% Sell ↓

Crescent Biopharma, Inc. insiders have been net buyers of shares over the past 12 Months, which may signal confidence in the company's outlook.

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 9, 2026

CBIO insider buying and selling by quarter

CBIO insider selling · CBIO insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling

2.8M1.4M0

2023 Q4

2024 Q1

2024 Q2

2024 Q3

2025 Q2

2025 Q3

2025 Q4

2026 Q2

Mobile shows last 4Q · Desktop shows full 8Q

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 9, 2026

Recent insider transactions

CBIO executive sell shares · CBIO board member insider trading · CBIO insider trading SEC filing

Showing 28 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

Date	Insider	Type	Shares	Price	Value	After trans.	Filing
Aug 7, 2024	Invus Public Equities, L.P. 10 percent owner	Sale	61,488	$0.18	$11K	6,578,438	Form 4
Aug 8, 2024	Invus Public Equities, L.P. 10 percent owner	Sale	260,873	$0.19	$50K	6,317,565	Form 4
Aug 5, 2024	Invus Public Equities, L.P. 10 percent owner	Sale	164,523	$0.19	$31K	6,695,658	Form 4
Aug 6, 2024	Invus Public Equities, L.P. 10 percent owner	Sale	55,732	$0.18	$10K	6,639,926	Form 4
Aug 1, 2024	Invus Public Equities, L.P. 10 percent owner	Sale	63,564	$0.22	$14K	7,146,381	Form 4
Aug 2, 2024	Invus Public Equities, L.P. 10 percent owner	Sale	286,200	$0.20	$57K	6,860,181	Form 4
Jul 26, 2024	Invus Public Equities, L.P. 10 percent owner	Sale	258,335	$0.24	$62K	8,330,729	Form 4
Jul 29, 2024	Invus Public Equities, L.P. 10 percent owner	Sale	363,949	$0.24	$86K	7,966,780	Form 4
Jul 30, 2024	Invus Public Equities, L.P. 10 percent owner	Sale	756,835	$0.22	$167K	7,209,945	Form 4
Jun 21, 2024	Rock Edwin Chief Medical Officer	Purchase	115,000	$0.27	$31K	680,403	Form 4
Jun 20, 2024	Rock Edwin Chief Medical Officer	Purchase	190,000	$0.25	$48K	565,403	Form 4
Jun 18, 2024	Hahn Brian M. SVP Finance, CFO	Purchase	17,500	$0.25	$4K	70,643	Form 4
Mar 29, 2024	JUNIUS DANIEL M Director	Award	5,209	$3.00	$16K	98,459	Form 4
Mar 29, 2024	King Rachel K. Director	Award	3,334	$3.00	$10K	515,194	Form 4
Mar 29, 2024	Goldberg Mark Alan Director	Award	4,584	$3.00	$14K	24,828	Form 4
Sep 22, 2023	Rock Edwin Chief Medical Officer	Purchase	30,403	$1.38	$42K	375,403	Form 4
Sep 21, 2023	Rock Edwin Chief Medical Officer	Purchase	35,000	$1.38	$48K	345,000	Form 4
Jun 1, 2023	Koenig Scott Director	Option	21,000	$0.60	$13K	36,750	Form 4
May 17, 2023	Hahn Brian M. SVP Finance, CFO	Sale	3,700	$1.95	$7K	53,143	Form 4
May 10, 2023	JUNIUS DANIEL M Director	Purchase	30,000	$1.56	$47K	93,250	Form 4
May 8, 2023	Johnson Bruce S SVP & Chief Commercial Officer	Purchase	13,500	$1.57	$21K	138,980	Form 4
Feb 24, 2023	Invus Public Equities, L.P. 10 percent owner	Purchase	100,000	$1.70	$170K	8,589,064	Form 4
Feb 23, 2023	Invus Public Equities, L.P. 10 percent owner	Purchase	200,000	$1.75	$351K	8,489,064	Form 4
Feb 22, 2023	Invus Public Equities, L.P. 10 percent owner	Purchase	150,000	$1.79	$269K	8,289,064	Form 4
Feb 21, 2023	Invus Public Equities, L.P. 10 percent owner	Purchase	50,000	$1.85	$93K	8,139,064	Form 4

Invus Public Equities, L.P.

10 percent owner

Sale

Date

Aug 7

61,488

Price

$0.18

Value

$11K

View Form 4 on SEC.gov

Invus Public Equities, L.P.

10 percent owner

Sale

Date

Aug 8

260,873

Price

$0.19

Value

$50K

View Form 4 on SEC.gov

Invus Public Equities, L.P.

10 percent owner

Sale

Date

Aug 5

164,523

Price

$0.19

Value

$31K

View Form 4 on SEC.gov

Invus Public Equities, L.P.

10 percent owner

Sale

Date

Aug 6

55,732

Price

$0.18

Value

$10K

View Form 4 on SEC.gov

Invus Public Equities, L.P.

10 percent owner

Sale

Date

Aug 1

63,564

Price

$0.22

Value

$14K

View Form 4 on SEC.gov

Invus Public Equities, L.P.

10 percent owner

Sale

Date

Aug 2

286,200

Price

$0.20

Value

$57K

View Form 4 on SEC.gov

Invus Public Equities, L.P.

10 percent owner

Sale

Date

Jul 26

258,335

Price

$0.24

Value

$62K

View Form 4 on SEC.gov

Invus Public Equities, L.P.

10 percent owner

Sale

Date

Jul 29

363,949

Price

$0.24

Value

$86K

View Form 4 on SEC.gov

Invus Public Equities, L.P.

10 percent owner

Sale

Date

Jul 30

756,835

Price

$0.22

Value

$167K

View Form 4 on SEC.gov

Rock Edwin

Chief Medical Officer

Purchase

Date

Jun 21

115,000

Price

$0.27

Value

$31K

View Form 4 on SEC.gov

Rock Edwin

Chief Medical Officer

Purchase

Date

Jun 20

190,000

Price

$0.25

Value

$48K

View Form 4 on SEC.gov

Hahn Brian M.

SVP Finance, CFO

Purchase

Date

Jun 18

17,500

Price

$0.25

Value

$4K

View Form 4 on SEC.gov

JUNIUS DANIEL M

Director

Award

Date

Mar 29

5,209

Price

$3.00

Value

$16K

View Form 4 on SEC.gov

King Rachel K.

Director

Award

Date

Mar 29

3,334

Price

$3.00

Value

$10K

View Form 4 on SEC.gov

Goldberg Mark Alan

Director

Award

Date

Mar 29

4,584

Price

$3.00

Value

$14K

View Form 4 on SEC.gov

Rock Edwin

Chief Medical Officer

Purchase

Date

Sep 22

30,403

Price

$1.38

Value

$42K

View Form 4 on SEC.gov

Rock Edwin

Chief Medical Officer

Purchase

Date

Sep 21

35,000

Price

$1.38

Value

$48K

View Form 4 on SEC.gov

Koenig Scott

Director

Option

Date

Jun 1

21,000

Price

$0.60

Value

$13K

View Form 4 on SEC.gov

Hahn Brian M.

SVP Finance, CFO

Sale

Date

May 17

3,700

Price

$1.95

Value

$7K

View Form 4 on SEC.gov

JUNIUS DANIEL M

Director

Purchase

Date

May 10

30,000

Price

$1.56

Value

$47K

View Form 4 on SEC.gov

Johnson Bruce S

SVP & Chief Commercial Officer

Purchase

Date

May 8

13,500

Price

$1.57

Value

$21K

View Form 4 on SEC.gov

Invus Public Equities, L.P.

10 percent owner

Purchase

Date

Feb 24

100,000

Price

$1.70

Value

$170K

View Form 4 on SEC.gov

Invus Public Equities, L.P.

10 percent owner

Purchase

Date

Feb 23

200,000

Price

$1.75

Value

$351K

View Form 4 on SEC.gov

Invus Public Equities, L.P.

10 percent owner

Purchase

Date

Feb 22

150,000

Price

$1.79

Value

$269K

View Form 4 on SEC.gov

Invus Public Equities, L.P.

10 percent owner

Purchase

Date

Feb 21

50,000

Price

$1.85

Value

$93K

View Form 4 on SEC.gov

⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar

1 / 2

▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About CBIO insider trading

CBIO insider trades

Crescent Biopharma, Inc. (CBIO) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including CBIO. Over the past 12 months, 0 insiders have filed transactions with the SEC. CBIO insiders have been primarily buying, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For Crescent Biopharma, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic

acquisitionOrDisposition field:

A = Acquisition (buy) · D = Disposition (sell)

RSU vesting (M-Exempt) excluded from sentiment

Form 4SEC filing required within 2 business days of any insider transaction

10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot

Open MktDirect purchase or sale on the open market (excludes awards, options)

Ownership SEC filings Financial statements Price history Forecast & ratings Earnings

Frequently asked questions

CBIO insider trading · 5 questions

The insiders of Crescent Biopharma, Inc. (CBIO) include executives and directors such as CBIO, among others. Over the past 12 months, 0 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

CBIO board member insider tradingwho are CBIO insidersCBIO insider rosterCrescent Biopharma, Inc. executives insider activity

▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026